Qinghaosu (artemisinin): Chemistry and pharmacology

Ying Li*

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Qinghaosu and its derivatives are widely used in the world as a new generation of antimalarial drug. Up to now, some important progresses of Qinghaosu research have been made, including synthesis of new Qinghaosu derivatives and analogs, investigation on their bioactivities and mode of actions. The present review briefly describes these efforts made by researchers in China, particularly in this Institute.

Keywords: Qinghaosu; artemisinin; structure modification; antimalarial activity; anticancer activity; immunosuppressive activity; mode of action

On 23rd May 1967, China established National Steering Group on antimalarial drug research, more than 60 institutes and 500 researchers joined in this project. After screening of over 5000 traditional Chinese medicines, Qinghaosu (QHS), an antimalarial principle, was isolated from Artemisia annua L in 1972[1, 2]. At the end of 1975, its unique chemical structure was elucidated, as a sesquiterpene lactone bearing a peroxy group, quite different from that of all known antimalarial drugs[3].

Early pharmacological and clinic studies showed QHS have rapid onset of action, low toxicity and high effect on both drug-resistant and drug-sensitive malaria. However, its shortcomings (poor solubility in water or oil; high rate of parasite recrudescence) needed to be overcome. In 1976, our Institute was charged with this important mission, and a research in relationship between chemical structure and activity immediately started.

First of all, the function of peroxy group for antimalarial activity was examined. The negative result of deoxyqinghaosu (Scheme 1) against P berghei in mice demonstrated that the peroxy group was essential. Soon afterwards, it was found that some other simple peroxides including monoterpene ascari dol had no antimalarial activity. These experimental results proved peroxy group to be an essential but not a sufficient factor. At that time, we noted the molecule contained a rare segment -O-C-O-C-O-C=O, and realized that whole molecular skeleton might play an important role for antimalarial activity.

When dihydroartemisinin (DHA) was found to be more active than QHS, but was still with poor solubility and lower stability (as a lactol) than QHS, we decided to prepare its derivatives. In 1976–1977, over 50 derivatives of DHA were synthesized (Scheme 1) and evaluated[4, 5]. The first 25 compounds (in oil solution) were tested in mice infected chloroquine-resistant P berghei though intramuscular injection[6]. Most of these derivatives showed higher activity than QHS (SD50 6.20 mg/kg) and DHA (SD50 3.65 mg/kg). In the ether series, SM 224 (R=CH3, SD50 1.02 mg/kg) is more active than QHS. In the ester series, SM 189 (R=CH3, SD50 0.88 mg/kg) is more active than DHA.

Scheme 1. Synthesis of Qinghaosu derivatives.
active than SM 227 (R=C_2H_5, SD_{50} 1.95 mg/kg) and others. Then, SM 224, SM 108 (ester, R=C_2H_5, SD_{50} 0.66 mg/kg) and SM 242 (carbonate, R=n-C_3H_7, SD_{50} 0.50 mg/kg) were compared with regard to activity, stability, toxicity and cost. Because SM 224 was highly soluble in oil and more stable than others, it was selected as candidate and named as artemether.

At the same period, water-soluble sodium artesunate (ester, R=COCH_2CH_2COONa) was developed by the Guilin Pharmaceutical Factory[7]. QHS suppository in 1986; artemether oil injection and sodium artesunate aqueous injection in 1987 were approved as new antimalarial drugs. Since then, other new antimalarial drugs such as dihydroartemisinin, coartem (artemether and benflumetol), co-naphthoquine (naphthoquine phosphate and QHS), compound-dihydroartemisinin were successively developed in China[1, 2].

Since 1980s, millions malaria patients in the world (mainly in China, Southeast Asia and Africa) were saved by administration of QHS, QHS derivatives and their combinations. Artemether, artesunate and coartem have been enrolled in WHO’s “List of Essential Medicines”.

Artemisinins can kill drug-resistant \textit{P falciparum}, its antimalarial mechanism must be different from that of the previously-used antimalarial drugs. Elucidation of its mode of action is really an interesting project. Up to now, many research papers have been published[8–14]. Chinese researchers first reported in 1979 that artemisinin drugs had a direct parasiticidal action against \textit{P falciparum} in the erythrocytic stage both in vitro and in vivo, and observed their morphologic changes under the electron microscope[15, 16]. The main pathological ultrastructural changes caused by QHS were quick damage of the membrane system of the asexual forms of parasites, the swelling and spiral deformation of the membrane of food vacuoles, limiting membrane and the membrane of mitochondria, followed by swelling of the nuclear membrane and endoplasmic reticulum. Among the latter results made in China[17–21], a series of reaction of artemisinins and Fe^{2+}, which involves the intermediate of oxygen-centered or carbon-centered free radicals, is noteworthy.

For exploring the mode of action, reaction of QHS and Fe^{2+} was carefully studied by Chinese chemists[22, 23]. The major products tetrahydrofuran 3 and 3-hydroxy deoxyqinghaosu 4 were proposed to be derived from primary C-centered free radical 1 and secondary C-centered free radical 2, respectively, as shown in Scheme 2. In addition, the electron spin resonance (ESR) signals of the C-centered free radicals were detected[23, 24].

It is worthy to note that compound 3 and 4 are also the major metabolites of QHS in vivo or in human[25, 26].

With the clarification on the C-centered free radicals participation mechanism, it is then interested whether this free radical mechanism is related to its antimalarial activity. Thus, the stable and UV-detectable C-12 aromatic substituted derivatives of QHS were synthesized[27]. Using the usual Lewis acid as the catalyst, the Friedel-Crafts alkylation gave the desired product 2’,4’-dimethoxyphenyl deoxoartemisinin 5 and also 11α-methyl epimer 6 as the by-product (Scheme 3). These products were separated and subjected to both bioassay and chemical reaction with ferrous ion. It is interesting to find that the derivative with normal configuration at C-11 showed higher antimalarial activity and also higher chemical reactivity in the reaction with ferrous ion. On the contrary, the 11α-methyl epimer 6 was obviously less active and almost inert to the reaction with ferrous ion (Scheme 3, Table 1).

In the case of 11α and 11β-epimers of α-hydroxy naphthyl deoxoqinghaosu, similar result was also obtained[28]. Their
lower activity may be attributed to the steric hindrance around O-1 atom in 11α-epimer, which blocks the way for Fe$^{2+}$ to attack O-1 (Figure 1).

The close relationship between antimalarial activity and the primary C-centered free radicals strongly suggests that the Fe$^{2+}$-induced cleavage of peroxide bond in artemisinins leads to C-centered free radicals, a highly potent alkylating species. Then, what targets would be alkylated? Up to now, a growing list shows that heme, heme-containing protein, translationally controlled tumor-associated protein (TCTP), sarcoplasmic reticulum Ca$^{2+}$ ATPase (SERCA)-type protein encoded by PfATP6 might be the targets\cite{14}. Recently, Chinese researchers reported that artemisinins are distributed to malarial mitochondria and directly impair their functions\cite{29}. As for process of alkylation of targets, there was another interesting topic. Considering that malaria-parasite-infected red blood cells have a high concentration of the reducing glutathione (GSH) and excess GSH might be responsible for protecting the parasite from the toxicity of heme, Chinese chemists have performed some reactions, such as artemisinins reacted with cysteine or GSH in the present of a catalytic amount of ferrous ion\cite{27, 30–33}. Successful isolation and identification of the cysteine-artemisinins or GSH-artemisinins adducts proved the formation of covalent bond in these adducts. It is instructive that the C-centered radicals derived from QHS and their derivatives could attack free cysteine and cysteine residue not only in peptide but also probably in protein.

The outstanding characteristics of QHS, including high antimalarial action, less significant side effects and less clinical resistance, impelled researchers to extend its medical application. As a result, hundreds of artemisinin derivatives and analogs were synthesized and widely assayed in China. So far, the successful examples are artemether and artesunate, which were found to be effective in the treatment of Schistosomiasis\cite{34, 35}. From 1993, artemether and artesunate were studied in randomized, double-blind, placebo-controlled trials in China, and approved as the prophylactic drugs for schistosomiasis japonica in 1996\cite{2}. Afterwards, they were found to have similar activity against S mansoni and S haematobium in other countries\cite{36}.

Since 1992, when this Institute first reported that some components of Artemisia annua L (such as artemisinic acid, artemisinin B) have antitumor activity \textit{in vitro}\cite{37, 38}, hundreds of papers have described the cytotoxicity of QHS and related compounds against tumor cells. Artesunate and DHA are most favorable molecules. In 2001 Efferth \textit{et al} reported that artesunate showed antitumor activity against 55 tumor cell lines, and it was most active against leukemia and colon cancer cell lines. It is notable that none of CEM leukemia sublines, resistant to doxorubicin, vincristin, methotrexate or hydroxyurea showed cross-resistance to artesunate\cite{39}. Since then, more new artemisinin derivatives and analogs were synthesized and tested against human cancer cells. Some compounds showed high activity at the nano- to micromolar range\cite{40}. For example, this Institute in collaboration with French cooperator found that a dihydroartemisinin ether containing cyanoaryl-methyl group 7 (Figure 2) was very active against P388 and A549 cell lines, as comparable to VCR, whereas its deoxy-analog 8 (Figure 2) was inactive. Thus peroxy group was proved to be essential for antitumor activity, like for antimalarial activity\cite{41, 42}. In addition, the type of derivative was proved to target G1 phase of the cell cycle\cite{41}. Thus far, antitumor activity of artemisinins and the underlying mechanisms have been

\begin{table}[h]
\centering
\caption{The ED50- and ED90-values against \textit{P berghei} K173 strain (administered orally to mice as suspensions in Tween 80).}
\begin{tabular}{|l|c|c|}
\hline
Compound & ED50 (mg/kg) & ED90 (mg/kg) \\
\hline
Artemeth  & 1 & 3.1 \\
5 & 1.27 & 5.27 \\
6 & 4.18 & 76.27 \\
\hline
\end{tabular}
\label{tab:table1}
\end{table}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1}
\caption{11α-methyl group blocks the attack of Fe$^{2+}$ on O-1.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2}
\caption{Some compounds with anticancer or immunosuppressive activity.}
\end{figure}
widely studied\textsuperscript{[61-69]}, however, few clinical trials were reported.

Antimalarial chloroquine was used as immunosuppressive agent. Therefore, the research on immunological activity of QHS and its derivatives became an attractive program in China in the 1980\textquotesingle s. At the begining, mainly new antimalarial drugs (QHS, artemether and arteunin) were studied in laboratories in China. Afterwards, the clinical trials of artesunate for the treatment of DLE, SLE, rheumatoid arthritis, polymorphous light eruption and chronic actinic dermatitis were conducted. Some clinical data were promising, for example, 56 patients with lupus erythematosus (DLE 16, SCLE 10, and SLE 30) were treated by sodium artesunate (iv 60 mg, once a day, 15 d a course, 2–4 courses), with effective rate at 94%, 90%, and 80%, respectively\textsuperscript{[60]}. To search for highly potent, low toxic immunosuppressive agents, more artemisinin derivatives were synthesized and screened in this Institute since 2001\textsuperscript{[51-54]}. Compounds with various structures were tested in respect to their cytotoxicity to lymphocyte, inhibition activity on ConA-induced T cell proliferation and LPS-induced B cell proliferation, in comparison with QHS, artesunate, artemether and cyclosporin A (CsA). At last, SM 735, SM 905, SM 933, and SM 934 (Figure 2) were selected and tested in the animal models for 2,4-dinitrofluorobenzene (DNFB)-induced delayed-type hypersensitivity (DTH) reaction, sheep red blood cell (SRBC)-induced antibody production, and experimental autoimmune encephalomyelitis (EAE). Up to date, a number of papers related their immuno-suppressive activity and possible mechanisms have been published mainly from this Institute\textsuperscript{[55-60]}. The preclinical research of SM 934 is in progress.

During the latter period of the program of the relationship between chemical structure and activity of artesiminins, SM 1044 was isolated as a by-product during the preparation of SM 934, and interestingly showed excellent antileukemia activity \textit{in vitro} and \textit{in vivo} in the Ruijin Hospital, Shanghai Jiao Tong University School of Medicine\textsuperscript{[65-69]}. These alkaline artesiminins may be a new kind of promising candidates. I sincerely hope they will be successfully developed for treatment of cancer, auto-immune or other diseases, like artemether as antimalarial drug 30 years ago.

References

1. Zhang JF. A detailed chronological record of project 523 and the discovery and development of Qinghaosu (Artemisinin). Guangzhou: Yangcheng Evening News Publisher; 2006. Chinese.

2. Li Y, Wu YL. A golden phoenix arising from the herbal net — A review and reflection on the study of antimalarial drug qinghaosu. Front Chem China 2010; 5: 357–422.

3. Liu JM, Ni MY, Fan JF, Tu YY, Wu ZH, Wu YL, et al. Structure and reactions of arteannuin. Acta Chim Sin 1979; 37: 129–43. Chinese.

4. Li Y, Yu PL, Chen YX, Li LQ, Gai YZ, Wang DS, et al. Synthesis of some derivatives of artesimin. Ke Xue Tong Bao 1979; 24: 667–9. Chinese.

5. Li Y, Yu PL, Chen YX, Li LQ, Gai YZ, Wang DS, et al. Studies on analogs of artesimin I. The synthesis of ethers, carboxylic esters and carbonates of dihydroartemisinine. Yao Xue Xue Bao 1981; 16: 429–39. Chinese.

6. Gu HM, Lu BF, Qu ZX. Antimalarial activities of 25 derivatives of artemisinine against chloroquine-resistant \textit{Plasmodium berghei}. Acta Pharmacol Sin 1980; 1: 48–50. Chinese.

7. Liu X. Study on artesimin derivatives. Yao Xue Tong Bao 1980; 15: 183. Chinese.

8. Meshnick SR, Tsang TW, Lin FB, Pan HZ, Chang CN, Kuypers F, et al. Activated oxygen mediates the antimalarial activity of qinghaosu. Prog Clin Biol Res 1989; 315: 95–104.

9. Meshnick SR, Tomas A, Ranz A, Xu CM, Pan HZ. Artemisinin (qinghaosu): the role of intracellular heme in its mechanism of antimalarial action. Mol Biochem Parasitol 1991; 49: 181–9.

10. Posner GH, Oh CH. A regiospecifically oxygen-18 labeled 1,2,4-trioxane: a simple chemical mode system to probe the mechanism(s) for the antimalarial activity of artesimin (qinghaosu). J Am Chem Soc 1992; 114: 8328–9.

11. Jefford CW. Why artesimin and certain synthetic peroxides are potent antimalarials. Implications for the mode of action. Curr Med Chem 2001; 8: 1803–26.

12. Olliolo PL, Haynes RK, Meunier B, Yuthavong Y. Possible modes of action of the artesimin-type compounds. Trends Parasitol 2001; 17: 122–6.

13. Posner GH, O’Neill PM. Knowledge of the proposed chemical mechanism of action and cytochrome P 450 metabolism of antimalarial trioxanes like artesimin allows rational design of new anti-malarial peroxides. Acc Chem Res 2004; 37: 394–404.

14. O’Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artesimin — the debate continues. Molecules 2010; 15: 1705–21.

15. Qinghaosu antimariala coordinating research group: Antimariala studies on qinghaosu. Chin Med J 1979; 92: 811–6.

16. Antimarial efficacy and mode of action of qinghaosu and its derivatives in experimental models. China Cooperative Research Group on qinghaosu and its derivatives as antimalarials. J Tradit Chin Med 1982; 2: 17–24.

17. Jin YG, Teng XH, Sun CP. Free radicals and mechanism of toxicity of sodium artesunate. Chin J Pharmocol Toxicol 1989; 2: 60–5. Chinese.

18. Wang YJ, Yuan LZ, Wang MD. Inhibition of sodium artesunate on rat erythrocyte membrane Na `-K`-exchanging ATPase \textit{in vitro}. Yao Xue Xue Bao 1995; 16: 524–6. Chinese.

19. Shi XC, Zhang QL, Wu K, Wang S, Sun CP, Wang QZ. Hemopoietotoxicity in pregnant mice and their embryos induced by free radicals derived from sodium artesunate. Chin J Pharmocol Toxicol 1997; 11: 226–8. Chinese.

20. Chen Y, Zhu SM, Chen HY, Li Y. Artesunate interaction with heme. Bioelectrochem Bioenerg 1988; 44: 295–300.

21. Cheng F, Shen JH, Luo XM, Zhu WL, Gu JD, Ji RY, et al. Molecular docking and 3-D-QSAR studies on the possible antimalarial mechanism of artesimin analogues. Bioorg Med Chem 2002; 10: 2883–91.

22. Wu WM, Yao ZJ, Wu YL, Jiang K, Wang YF, Chen HB, et al. Ferrous ion induced cleavage of the perox bond in qinghaosu and its derivatives and the DNA damage associated with this process. Chem Commun 1996; 18: 2213–4.

23. Wu WM, Wu YK, Wu YL, Yao ZJ, Zhou CM, Li Y, et al. A unified mechanism framework for the Fe(II)-induced cleavage of qinghaosu and derivatives/analogues. The first spin-trapping evidence for the earlier postulated secondary C-4 radical. J Am Chem Soc 1998; 120: 3316–25.

24. Butler AR, Gilbert BC, Hulme P, Irvine LR, Renton L, Whitwood AC. EPR evidence for the involvement of free radicals in the iron-catalysed decomposition of qinghaosu (artesiminin) and some derivatives:
Antimalarial action of some polycyclic endoperoxides. Free Rad Res 1998; 28: 471–6.

25 Zhu DY, Huang BS, Chen ZL, Yin ML, Yang YM, Dai ML, et al. Isolation and identification of the metabolite of artemisinin in human. Yao Xue Xue Bao 1993; 4: 194–7. Chinese.

26 Lee IS, Hufford CD. Metabolism of antimalarial sesquiterpene lactones. PharmacoI Ther 1990; 48: 345–55.

27 Wang DY, Wu YL, Liang J, Li Y. Further evidence for the participation of primary carbon-centered free-radicals in the antimalarial action of the the qinghaosu (artemisinin) series of compounds. ChemInform 2001; 32: 605–9.

28 Wang DY, Wu YK, Wu YL, Li Y, Shan F. Synthesis, iron(II)-induced cleavage and in vivo antimalarial efficacy of 10-(2-hydroxy-1-naphthyl)-deoxoqinghaosu (-deoxoartemisinin). J Chem Soc Perkin Trans 1. 1999: 1827–31.

29 Wang J, Huang L, Li J, Fan Q, Long Y, Li Y, et al. Artemisinin directly targets malaria mitochondria through its specific mitochondrial activation. PLoS One 2010; 5: e9582.

30 Wu YL, Chen HB, Jiang K, Li Y, Shan F, Wang DY, et al. Interaction of biomolecules with qinghaosu (artemisinin) and its derivatives in the presence of ferrous ion --- an explanation of antimalarial mechanism. Pure Appl Chem 1999; 71: 1139–42.

31 Wang DY, Wu YL. A possible antimalarial action mode of qinghaosu (artemisinin) series compounds. Alkylation of reduced glutathione by C-centered primary radicals produced from antimalarial compound qinghaosu and 12-(2,4-dimethoxyphenyl)-12-deoxoqinghaosu. Chem Commun 2000; 22: 2193–4.

32 Wu YK, Yue ZY, Wu YL. Interaction of qinghaosu (artemisinin) with cysteine sulfhydril mediated by traces of non-heme iron. Angew Chem Int Ed 1999; 38: 2580–2.

33 Wu WM, Chen YL, Zhai ZL, Xiao SH, Wu YL. Study on the mechanism of action of artemether against schisosomes — The identification of cysteine adducts of both carbon-centered free-radicals derived from artemether. Bioorg Med Chem Lett 2003; 13: 1645–7.

34 Chen DJ, Fu LF, Shao PP, Wu FZ, Fan CZ, Shu Y, et al. The experimental studies of artemisinin against Schistosoma japonicum in animals. Zhonghua Yi Xue Za Zhi 1980; 60: 422–5. Chinese.

35 Le WJ, Wang GF, You JQ, Xie RR, Mei JY. The experimental studies of artemisinin derivatives against Schistosoma japonicum in animals. Yao Xue Tong Bao 1980; 15: 182. Chinese.

36 Xiao SH, Tanner M, N’Goran EK, Utzinger J, Chollet J, Bergquist R, et al. Recent investigations of artemether, a novel agent for the prevention of Schistosomiasis japonica, mansoni and haematobia. Acta Trop 2002; 82: 175–81.

37 Sun WC, Han JX, Yang WY, Deng DA, Yue XF. Antitumor activities of 2 derivatives of artemisinic acid and artemisinin B, in vitro. Acta Pharmacol Sin 1992; 13: 541–3. Chinese.

38 Deng DA, Xu CH, Cai JC. Derivatives of artannuin B with antileukemia activity. Yao Xue Xue Bao 1992; 27: 317–20. Chinese.

39 Effert T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The antimalarial artesunate is also active against cancer. Int J Oncol 2001; 18: 767–73.

40 Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012; 2012: 247597.

41 Li Y, Shan F, Wu JM, Wu GS, Ding J, Xiao D, et al. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg Med Chem Lett 2001; 11: 5–8.

42 Wu JM, Shan F, Wu GS, Li Y, Ding J, Xiao D, et al. Synthesis and cytotoxicity of artemisinin derivatives containing cyanoaryl methyl group. Eur J Med Chem 2001; 36: 240–5

43 Efforth T. Willmar Schwabe Award 2006: Antiplasmodial and anti-tumor activity of artemisinin from bench to bedside. Planta Med 2007; 73: 299–309.

44 Liu Y, Lok CH, Ko BCB, Shum TYT, Wong MK, Che CM. Subcellular localization of a fluorescent artemisinin derivative to endoplasmic reticulum. Org Lett 2010; 12: 1420–3.

45 Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, et al. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drug 2010; 21: 423–32.

46 Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, et al. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther 2008; 7: 1017–23.

47 Lu JJ, Meng LH, Shankavaram UT, Zhao CH, Tong LJ, Chen G, et al. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010; 80: 22–30.

48 Lu JJ, Chen SM, Zhang XW, Ding J, Meng LH. The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest New Drugs 2011; 29: 1276–83.

49 Lu JJ, Chen SM, Ding J, Meng LH. Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line. Mol Cell Biochem 2012; 360: 329–37.

50 Yu QB, Gao YX. 56 cases of lupus erythematosus treated with artesunate. Zhonghua Pi Fu Ke Za Zhi 1997, 30: 51–2. Chinese.

51 Yang ZS, Zhou WL, Sui Y, Wang JX, Wu JM, Zhou Y, et al. Synthesis and immunosuppressive activity of new artemisinin derivatives. Part I. [12 (β or α)-Dihydroartemisinininoxyl] phenoxyl aliphatic acids/esters. J Med Chem 2005; 48: 4608–17.

52 Yang ZS, Wang JX, Zhou Y, Zuo JP, Li Y. Synthesis and immunosuppressive activity of new artemisinin derivatives. Part 2: 2-[12(β or α)-Dihydro-artemisininoxymethyl- (or 1′-ethyl) phenoxyl propanic acids and esters. Bioorg Med Chem 2006; 14: 8043–9.

53 Zhang JX, Wang JX, Zhang Y, Zuo JP, Wu JM, Sui Y, et al. Synthesis and immunosuppressive activity of new artemisinin derivatives containing polyethylene glycol group. Yao Xue Xue Bao 2006; 41: 65–70. Chinese.

54 Li Y, Zhu YM, Jiang HJ, Pan JP, Wu GS, Wu JM, et al. Synthesis and antimalarial activity of artemisinin derivatives containing an amino group. J Med Chem 2000; 43: 3635–40.

55 Zhou WL, Wu JM, Wu QL, Wang JX, Zou Y, Zou R, et al. A novel artemisinin derivative, 3-(12-beta-arteriminsoxy) phenoxyl succinic acid (SM735), mediates immunosuppressive effects in vivo and in vitro. Acta Pharmacol Sin 2005; 26: 1352–8.

56 Wang JX, Tang W, Shi LP, Wan J, Zou R, Ni J, et al. Investigation of the immunosuppressive activity of artesunate on T cell activation and proliferation. Br J Pharmacol 2007: 150: 652–61.

57 Wang Z, Qiu J, Guo TB, Liu A, Wang Y, Li Y, et al. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J Immunol 2007; 179: 5958–65.

58 Wang JX, Tang W, Shi LP, Wan J, Zou R, Ni J, et al. Investigation of the immunosuppressive activity of artesunate on T-cell activation and proliferation. Br J Pharmacol 2007: 150: 652–61.

59 Wang JX, Tang W, Yang ZS, Wan J, Shi LP, Zhang Y, et al. Suppressive effect of a novel water-soluble artemisinin derivative SM 905 on T cell activation and proliferation in vitro and in vivo. Eur J Pharmacol 2007; 564: 211–8.

60 Wang JX, Tang W, Zhou R, Wan J, Shi LP, Zhang Y, et al. The new water-soluble artemisinin derivative SM 905 ameliorates collagen-
induced arthritis by suppression of inflammatory and Th17 responses. Br J Pharmacol 2008, 153: 1303–10.
61 Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP. SM 905, a novel artemisinin derivative, inhibition of NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappa B pathways in RAW 264.7 macrophages. Acta Pharmacol Sin 2009; 30: 1428–35.
62 Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, et al. SM 934, a water-soluble derivative of artemisinin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol 2009; 9: 1509–17.
63 Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum 2011; 63: 2445–55.
64 Hou LF, He SJ, Li X, Wan CP, Yang Y, Zhang XH, et al. SM934 treated lupus-prone NZB×NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One 2012; 7: e32424.
65 Li Y, Zhu Y, Zhang Y, Zhou JY, Cai L, Xie SW, inventors; Qinghaosu dimer containing nitrogen atom(s), its preparation and use. Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Shanghai Institute of Planned Parenthood Research. Chinese Patent 201110034154.9, 2011 Jan 31.
66 Mi JQ, Li Y, Liu JJ, Zhang Y, Cai X, Wang ZY, inventors; Use of aqinghaosu dimer. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Chinese Patent 201110034201.X, 2011 Jan 31.
67 Mi JQ, Li Y, Ni RM, Zhang Y, Wang J, Cai X, Wang ZY, inventors; Qinghaosu derivative and its salt, a new type of agent for treatment of acute leukemia. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Chinese Patent 201210011774.5, 2012 Jan 16.
68 Mi JQ, Li Y, Ni RM, Zhang Y, Wang J, Cai X, Wang ZY, inventors; Qinghaosu derivative and its salt, a new type of agent for treatment of acute leukemia. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Chinese Patent 201210012386.9, 2012 Jan 16.
69 Mi JQ, Li Y, Peng Y, Zhang Y, Wang J, Cai X, Wang ZY, inventors; Qinghaosu derivative and its salt, a new type of agent for treatment of acute myelocytic leukemia. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Chinese Patent 201210012204.8, 2012 Jan 16.